Epoch Investment Partners Inc. Sells 486,365 Shares of Kenvue Inc. $KVUE

Epoch Investment Partners Inc. reduced its stake in Kenvue Inc. by 10.1% in Q2, selling 486,365 shares. Kenvue's stock has a consensus "Hold" rating with a target price of $20.23. The stock opened at $16.97, with a market cap of $32.51 billion. Kenvue reported Q3 earnings of $0.28 per share, slightly above estimates, and announced a quarterly dividend of $0.2075 per share.

Epoch Investment Partners Inc. lowered its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 10.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,308,207 shares of the company's stock after selling 486,365 shares during the period. Epoch Investment Partners Inc. owned 0.22% of Kenvue worth $90,171,000 at the end of the most recent quarter.

3 Smart Defensive Stocks for an Uneasy Market

A number of other large investors have also bought and sold shares of KVUE. Baird Financial Group Inc. lifted its position in shares of Kenvue by 10.6% during the 2nd quarter. Baird Financial Group Inc. now owns 781,062 shares of the company's stock valued at $16,348,000 after buying an additional 75,088 shares during the last quarter. Guggenheim Capital LLC increased its holdings in Kenvue by 33.3% in the 2nd quarter. Guggenheim Capital LLC now owns 255,061 shares of the company's stock worth $5,338,000 after acquiring an additional 63,736 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in Kenvue by 32.0% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 9,576 shares of the company's stock valued at $200,000 after acquiring an additional 2,321 shares during the period. Invesco Ltd. lifted its holdings in Kenvue by 11.0% during the second quarter. Invesco Ltd. now owns 17,818,771 shares of the company's stock valued at $372,947,000 after purchasing an additional 1,759,065 shares during the last quarter. Finally, Independent Franchise Partners LLP boosted its position in Kenvue by 233.4% during the second quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company's stock worth $654,388,000 after purchasing an additional 21,886,537 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on KVUE. Canaccord Genuity Group reissued a "hold" rating and issued a $15.00 price target (down previously from $26.00) on shares of Kenvue in a research report on Wednesday, October 29th. Evercore ISI set a $18.00 price objective on shares of Kenvue in a research note on Tuesday, October 28th. Bank of America dropped their target price on Kenvue from $25.00 to $21.00 and set a "buy" rating on the stock in a research report on Wednesday, October 8th. Edward Jones lowered Kenvue from a "strong-buy" rating to a "hold" rating in a report on Monday, November 3rd. Finally, Johnson Rice reiterated a "neutral" rating on shares of Kenvue in a research report on Tuesday, October 28th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $20.23.

Sticker Shock: Why Kimberly-Clark's Sell-Off Is an Overreaction

Get Our Latest Stock Analysis on KVUE

Kenvue Price Performance

KVUE opened at $16.97 on Friday. The firm has a market capitalization of $32.51 billion, a P/E ratio of 22.63 and a beta of 0.60. Kenvue Inc. has a one year low of $14.02 and a one year high of $25.17. The company has a fifty day moving average price of $16.08 and a 200-day moving average price of $19.40. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69.

Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.27 by $0.01. The company had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The firm's revenue was down 3.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.28 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th were issued a dividend of $0.2075 per share. The ex-dividend date of this dividend was Wednesday, November 12th. This represents a $0.83 annualized dividend and a dividend yield of 4.9%. Kenvue's payout ratio is presently 110.67%.

Kenvue Company Profile

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Should You Invest $1,000 in Kenvue Right Now?

Before you consider Kenvue, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.

While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here